GAMMA Investing LLC Purchases 3,566 Shares of Twist Bioscience Co. (NASDAQ:TWST)

GAMMA Investing LLC boosted its position in Twist Bioscience Co. (NASDAQ:TWST) by 1,896.8% during the second quarter, HoldingsChannel.com reports. The fund owned 3,754 shares of the company’s stock after buying an additional 3,566 shares during the quarter. GAMMA Investing LLC’s holdings in Twist Bioscience were worth $185,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. American International Group Inc. boosted its holdings in shares of Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after purchasing an additional 213 shares in the last quarter. D.A. Davidson & CO. boosted its stake in Twist Bioscience by 3.4% in the fourth quarter. D.A. Davidson & CO. now owns 16,774 shares of the company’s stock valued at $618,000 after buying an additional 554 shares in the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience in the fourth quarter valued at about $30,000. Swiss National Bank raised its stake in Twist Bioscience by 0.8% during the first quarter. Swiss National Bank now owns 114,000 shares of the company’s stock worth $3,911,000 after acquiring an additional 900 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in Twist Bioscience by 10.2% during the first quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock worth $496,000 after acquiring an additional 1,336 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TWST shares. Scotiabank lifted their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Evercore ISI boosted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Guggenheim started coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Finally, TD Cowen boosted their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Insider Activity at Twist Bioscience

In other news, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $47,120.94. Following the completion of the sale, the senior vice president now owns 90,593 shares in the company, valued at approximately $4,650,138.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $51.33, for a total transaction of $47,120.94. Following the completion of the transaction, the senior vice president now directly owns 90,593 shares in the company, valued at $4,650,138.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Emily M. Leproust sold 2,408 shares of Twist Bioscience stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the transaction, the chief executive officer now owns 507,578 shares of the company’s stock, valued at approximately $26,053,978.74. The disclosure for this sale can be found here. Insiders have sold a total of 11,289 shares of company stock worth $577,943 in the last 90 days. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Price Performance

NASDAQ TWST traded up $3.02 on Tuesday, reaching $48.35. The company had a trading volume of 613,068 shares, compared to its average volume of 1,049,199. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of -14.08 and a beta of 1.80. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90. The business has a 50 day moving average of $50.58 and a two-hundred day moving average of $41.41.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. During the same period in the prior year, the company posted ($1.01) EPS. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. As a group, research analysts predict that Twist Bioscience Co. will post -3.08 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.